NCT03913806View on ClinicalTrials.gov

FLuoresence Image Guided Surgery With A VEGF-targeted Tracer in Soft-tissue Sarcomas in Humans Approach With Bevacizumab-IRDye 800CW

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

December 22, 2019

Study Completion Date

January 1, 2020

Conditions
Soft Tissue Sarcoma
Interventions
DRUG

Bevacizumab-IRDye800CW

dose finding:10mg; 25mg; 50mg

Trial Locations (1)

9713 GZ

University Medical Center Groningen, Groningen

All Listed Sponsors
lead

University Medical Center Groningen

OTHER

NCT03913806 - FLuoresence Image Guided Surgery With A VEGF-targeted Tracer in Soft-tissue Sarcomas in Humans Approach With Bevacizumab-IRDye 800CW | Biotech Hunter | Biotech Hunter